Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi (TM)): multidisciplinary perspective

Gisbert Javier P.; Gaffney Karl; Young DavidEbbers Hans C.Girolomoni Giampiero

首页> 外文期刊>Expert opinion on biological therapy >Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi (TM)): multidisciplinary perspective

【24h】

Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi (TM)): multidisciplinary perspective

机译：Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi (TM)): multidisciplinary perspective

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Introduction: This review provides an overview of data from trials and real-world studies available for 565 (Imraldi (TM)) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology. Areas covered: A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken. Expert opinion: Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immunemediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments.

著录项

来源
《Expert opinion on biological therapy》 |2022年第6期|109-121|共13页
作者
Gisbert Javier P.; Gaffney Karl; Young DavidEbbers Hans C.Girolomoni Giampiero;
展开▼
作者单位

Hosp Univ La Princesa,Univ Autonoma Madrid UAM;

Rheumatol Dept,Norfolk & Norwich Hosp NHS Fdn Trust;

Dept Gastroenterol,Univ Hosp Southampton NHS Fdn TrustBiogen Intl GmbHDept Med,Univ Verona;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类治疗学;
关键词
Biosimilar; adalimumab; anti-TNF; SB5; Imraldie (R); dermatology; gastroenterology; rheumatology; multidisciplinary; MODIFYING ANTIRHEUMATIC DRUGS; INFLAMMATORY-BOWEL-DISEASE; RHEUMATOID-ARTHRITIS; COST-EFFECTIVENESS; INTERIM ANALYSIS; REAL-WORLD; ORIGINATOR; INFLIXIMAB; SWITCH; INTERCHANGEABILITY;

Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi (TM)): multidisciplinary perspective

摘要

著录项

相关主题

期刊订阅